文献速递胸部肿瘤

肿瘤生物标志物指导治疗时代新型非小细胞肺癌治疗的社会经济不平等:公共资助医疗体系中的基于人群队列研究

Socioeconomic Inequalities in Novel NSCLC Treatments During the Era of Tumor Biomarker-Guided Therapy: A Population-Based Cohort Study in a Publicly Funded Health Care System.
PubMed 文献 · J Thorac Oncol · 2023-05-04

该回顾性分析纳入2012年1月1日至2017年12月31日英格兰国家癌症登记数据库中90,785例经组织学确诊的IV期非小细胞肺癌患者,评估居住地区贫困程度与新型抗癌治疗利用的关系。多变量分析显示,最贫困地区患者接受任何新型治疗的可能性低于最富裕地区(mvOR=0.45,95%CI:0.41-0.49),靶向治疗的不平等程度(mvOR=0.39,95%CI:0.35-0.43)略强于免疫检查点抑制剂(mvOR=0.58,95%CI:0.51-0.66)。即使在免费医疗的英国国家医疗服务体系下,仍存在明显的社会经济不平等。

要点

  • 最贫困地区患者接受任何新型治疗的可能性低于最富裕地区(mvOR=0.45,95%CI:0.41-0.49)。
  • 靶向治疗利用的贫困相关不平等(mvOR=0.39,95%CI:0.35-0.43)略强于免疫检查点抑制剂(mvOR=0.58,95%CI:0.51-0.66)。
  • 在免费医疗的英国国家医疗服务体系下仍存在明显的社会经济不平等。

核心结论

  • 在英格兰国家医疗服务体系内,IV期非小细胞肺癌患者的新型治疗利用存在明显的社会经济不平等,最贫困地区患者接受任何新型治疗、靶向治疗和免疫检查点抑制剂的可能性均低于最富裕地区。
  • 作者指出这些发现对公平提供已改变转移性肺癌结局的药物具有重要意义,并认为现在需要进一步探索潜在原因。

研究设计与样本

  • 回顾性分析,数据来源于英格兰国家基于人群的癌症登记数据库及关联的系统性抗癌治疗数据库。
  • 纳入2012年1月1日至2017年12月31日经组织学确诊的IV期非小细胞肺癌患者90,785例。
  • 采用多变量逻辑回归评估诊断时居住地区贫困程度(以多重剥夺指数收入域五分位数衡量)与新型抗癌治疗利用可能性之间的关联。

主要发现

  • 最贫困地区患者接受任何新型治疗的可能性低于最富裕地区(mvOR=0.45,95%CI:0.41-0.49)。
  • 靶向治疗利用方面,最贫困地区与最富裕地区相比mvOR=0.39(95%CI:0.35-0.43)。
  • 免疫检查点抑制剂利用方面,最贫困地区与最富裕地区相比mvOR=0.58(95%CI:0.51-0.66)。
  • 贫困与治疗利用的关联在靶向治疗中略强于免疫检查点抑制剂。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Socioeconomic inequalities in the utilization of conventional NSCLC treatments are well documented. Nevertheless, it is not known whether these inequalities are also observed with novel anticancer therapies. This study evaluated associations between deprivation and utilization of novel anticancer therapies targeting tumor biology, the immune system, or both, within the English national publicly funded health care system. METHODS: A retrospective analysis of 90,785 patients diagnosed with having a histologically confirmed stage IV NSCLC from January 1, 2012, to December 31, 2017, sourced from the English national population-based cancer registry and linked Systemic Anti-Cancer Therapy database, was undertaken. Multivariable logistic regression evaluated the likelihood of novel anticancer therapy utilization by deprivation category of area of residence at diagnosis (measured by quintiles of the income domain of the index of multiple deprivation). RESULTS: Multivariable analyses revealed marked treatment inequalities by deprivation. Patients residing in the most deprived areas were more than half as likely to use any novel therapy (multivariable OR [mvOR] = 0.45, 95% confidence interval [CI]: 0.41-0.49) compared with patients residing in the most affluent areas. Deprivation associations with treatment utilization were slightly stronger with targeted treatments ([most versus least deprived] mvOR = 0.39, 95% CI: 0.35-0.43) than immune checkpoint inhibitors (mvOR = 0.58, 95% CI: 0.51-0.66). CONCLUSIONS: There are marked socioeconomic inequalities in NSCLC novel treatment utilization, even in the English National Health Service where treatment is free at the point of delivery. These findings have important implications for equitable delivery of drugs, which have transformed outcomes in metastatic lung cancer. Further work exploring the underlying causes is now needed.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Norris RP, Dew R, Greystoke A, et al. Socioeconomic Inequalities in Novel NSCLC Treatments During the Era of Tumor Biomarker-Guided Therapy: A Population-Based Cohort Study in a Publicly Funded Health Care System. J Thorac Oncol. 2023. PMID: 37146751. doi:10.1016/j.jtho.2023.04.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。